Epidermal growth factor receptor inhibitors are used to treat advanced lung cancer patients
for almost a decade. Current knowledge on their role in the first or subsequent lines of …

Drugs that target the epidermal growth factor receptor (EGFR) have had a major impact on
the treatment of non–small cell lung cancer (NSCLC). The use of these drugs has also …

Although the epidermal growth factor receptor tyrosine kinase inhibitors gefitinib and
erlotinib can produce dramatic and durable tumor responses, not all patients with non-small …

Tyrosine kinase inhibitors directed against the epidermal growth factor receptor (EGFR) are
the first molecular-targeted agents to be approved in the US and other countries for the …

Chemotherapy is the standard of care for patients with advanced non‐small cell lung cancer
(NSCLC). Over the past 20 years, advances in chemotherapy have shown minimal …

Over the past decade our evolving knowledge and understanding of cancer biology has
allowed rapid progression in the development of targeted cancer therapy. Improving lung …

Non-small cell lung cancer (NSCLC) is the major cause of cancer-related deaths in the USA
and worldwide. Most patients present with advanced disease, and treatment options for …

Lung cancer is the most common cause of cancer death. The vast majority of patients
present with non-small cell lung cancer (NSCLC) in advanced inoperable stages. The …

The identification of certain molecular mechanisms underlying lung carcinogenesis and
progression has led to the development of targeted agents against different families of …

Lung cancer will be diagnosed in 230,000 patients in the US in 2013. Adenocarcinoma will
be the most common histology, and 10% of lung cancers will be diagnosed in never or …